eMedicine Specialties > Pediatrics: Surgery > Otolaryngology

Otosclerosis: Treatment & Medication

Author: Peter S Roland, MD, Professor, Department of Neurological Surgery, Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, Director of Clinical Center for Auditory, Vestibular and Facial Nerve Disorders, Chief of Pediatric Otology, University of Texas Southwestern Medical Center; Adjunct Professor of Communicative Disorders, School of Human Development.
Contributor Information and Disclosures

Updated: Oct 16, 2008

Treatment

Medical Care

For the vast majority of patients with otosclerosis, the principal goal is remediation of hearing loss. Only a small minority of patients have vestibular symptoms that are pronounced and warrant treatment solely on that basis.

  • Use of sodium fluoride to arrest development of otosclerosis was championed by Shambaugh and was fairly widespread in the 1960s-70s.3,4 Fluoride ions replace the usual hydroxyl group in hydroxy apatite. The result is a fluorapatite complex resistant to osteoclastic degradation. Sodium fluoride therapy is used less commonly now, but it still has supporters. The recommended dosage is 20-120 mg/d. Effectiveness is monitored by noting the disappearance of Schwartze sign, repeated audiometric testing, and follow-up CT scanning.
  • Hearing loss can be effectively remediated using amplification. Hearing aids can often provide almost complete elimination of the conductive hearing loss and aided thresholds can return to near normal. Although useful, hearing aids are poorly accepted for various reasons. The presence of the occlusive mold within the external auditory canal produces an unpleasant effect, termed the canal occlusion effect. Individuals who use hearing aids report that the effect produces sound quality similar to that of "hearing in a barrel." Moreover, the devices are generally not worn at night, are sometimes difficult to adjust, can produce shrill screeching noises (as a result of feedback), and do not provide natural sound quality. Additionally, in 20th century American society, hearing aids carry the stigma of infirmity or disability.

Surgical Care

Most patients elect surgical repair. Surgery for otosclerosis is very successful, and more than 90% of patients experience complete elimination of conductive hearing loss (ie, <10 dB of residual air bone gap). The operation is a day surgical procedure that can be performed under general or local anesthesia. The operation is completed in 45-60 minutes.

  • The first step in the surgical procedure is elevation of the tympanic annulus from its sulcus, such that the tympanic membrane can be reflected anteriorly. Elevation provides access to the entire posterior middle ear, including the ossicular chain. Once the drum has been elevated, small instruments are used to palpate the ossicular chain and to confirm that the stapes is fixed and immobile within the oval window niche. Once the diagnosis is confirmed, incisions are made in the mucosa around the footplate to free it from the remainder of the middle ear mucosa. Generally, a small vessel extends anteriorly just over the anterior lip of the oval window niche. This vessel can produce significant bleeding and should be controlled prior to attempted footplate removal so that the bleeding can be controlled before the oval window is opened.
  • Prior to removal of the stapes, a graft must be obtained that can be used to seal the open oval window after footplate removal.
    • A small piece of vein can be taken from the hand. The hand provides an excellent graft; however, a second operative site must be exposed and prepared. Tragal perichondrium is used more commonly. Perichondrium can be obtained from the tragus of the ear within the same surgical field.
    • A measurement is made to determine how long the prosthesis needs to be.
    • Once the graft material has been obtained and cut to the appropriate size, a control hole is made in the center of the fixed footplate. After a control hole has been made, the incudostapedial joint is separated, and the stapedius tendon is cut. The suprastructure of the stapes then is fractured away. Because the stapes footplate is fixed in the oval window, pressure on the crura causes them to fracture at their base. The control hole now is slightly enlarged (0.1 mm) with a right angle hook. Larger instruments are used to extract the remainder of the footplate. The graft then is placed over the open oval window, and the prosthesis is positioned to span the gap between the distal portion of the incus and the grafted oval window. The eardrum is returned to anatomic position, and the procedure is terminated after the canal has been filled with nonototoxic antibacterial ointment.
  • As an alternative to removal of the entire footplate, a small hole can be drilled into the footplate itself just sufficient to accommodate the end of the prosthesis. Such a procedure is referred to as a stapedectomy as opposed to the classic stapedectomy, in which the complete footplate is removed. Both procedures have high success rates, and little long-term difference between them has been demonstrated.
  • Various operative and postoperative complications are possible.
    • In 1-2% of cases, all hearing is lost in the operated ear, resulting in complete sensorineural hearing loss (SNHL). Such a catastrophic perioperative loss is unremediable. Neither revision surgery nor amplification provides any meaningful hearing improvement. The exact circumstances that create such catastrophic injuries are unclear. However, cases of complete SNHL that follow an entirely uneventful surgical procedure are well documented.
    • Permanent facial nerve injury occurs in fewer than 1 per 100 (probably <1 per 1000) cases.
    • In 1-2% of cases, a tympanic membrane perforation results from elevation of the eardrum. Such tympanic membrane perforations are generally in the posterior quadrant and are relatively easy to repair.
    • Because the chorda tympani lies directly across the ossicular chain, it must either be mobilized or, in many cases, divided to access the oval window niche. Consequently, some alteration of taste may follow the operation. This condition generally resolves in a few weeks to a couple of months.
    • Dysequilibrium and vertigo with nausea and vomiting are frequent in the immediate postoperative period and often last for several days. Long-term balance disturbance occurs but is very uncommon.
    • Individuals may develop tinnitus after the operation. Some patients who had tinnitus preoperatively have worse tinnitus postoperatively. However, most patients who experience hearing improvement report either significant improvement in their tinnitus or no meaningful change.
  • The operation is performed in only one ear at a time; the worst-hearing ear should be approached first. Many patients desire correction of the second ear if the operation on the first ear was successful. The second ear should be subjected to surgery only if the surgeon is convinced that the operation has been successful in the first ear and that the result is permanent. As a general rule, 3-12 months should elapse between the first and second operations.

Medication

Sodium fluoride and calcium are the only drugs used in the treatment of otosclerosis; however, because it is typically not apparent until late adolescence, studies in pediatrics have not been pursued.

Mineral and vitamin supplements

Sodium fluoride is thought to mature the active focus of otospongiosis and to limit progression of the disease, especially sensorineural hearing loss (SNHL).


Sodium fluoride (Fluoritab, Luride, Pediaflor)

Fluoride is an element essential for the development of healthy teeth and bones.

Adult

20-120 mg/d PO divided tid
Often combined with vitamin D 400 IU/d and calcium carbonate 1.25 g (500 mg elemental calcium) PO tid to enhance absorption

Pediatric

Not established
Adolescents: Administer as in adults

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

GI upset common; may cause staining of the teeth


Vitamin D

Stimulates calcium and phosphate absorption from small intestine and promotes calcium release from bone into blood.

Adult

400 IU/d PO

Pediatric

Not established
Adolescents: Administer as in adults

Colestipol, mineral oil, and cholestyramine may decrease vitamin D absorption from small intestine; thiazide diuretics may increase effects

Documented hypersensitivity; hypercalcemia, malabsorption syndrome

Pregnancy

A - Fetal risk not revealed in controlled studies in humans

Precautions

Pregnancy category C if dose exceeds RDA; caution in impaired renal function, renal stones, heart disease, or arteriosclerosis


Calcium carbonate (Oystercal)

Used in combination with vitamin D and sodium fluoride.

Adult

1.25 g (500 mg elemental calcium) PO tid

Pediatric

Not established
Adolescents: Administer as in adults

May decrease effects of tetracyclines, atenolol, salicylates, iron salts, and fluoroquinolones; large intakes of dietary fiber may decrease calcium absorption and levels

Renal calculi, hypercalcemia, hypophosphatemia, renal or cardiac disease, digitalis toxicity

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in digitalized patients and respiratory failure or acidosis

More on Otosclerosis

Overview: Otosclerosis
Differential Diagnoses & Workup: Otosclerosis
Treatment & Medication: Otosclerosis
Follow-up: Otosclerosis
References

References

  1. Gordon MA. The genetics of otosclerosis: a review. Am J Otol. Nov 1989;10(6):426-38. [Medline].

  2. Ealy M, Chen W, Ryu GY, et al. Gene expression analysis of human otosclerotic stapedial footplates. Hear Res. Jun 2008;240(1-2):80-6. [Medline].

  3. Shambaugh GE Jr, Causse J. Ten years experience with fluoride in otosclerotic (otospongiotic) patients. Ann Otol Rhinol Laryngol. Sep-Oct 1974;83(5):635-42. [Medline].

  4. Shambaugh GE Jr, Petrovic A. Effects of sodium fluoride on bone. Application to otosclerosis and other decalcifying bone diseases. JAMA. Jun 10 1968;204(11):969-73. [Medline].

  5. Causse JR, Causse JB, Bretlau P, et al. Etiology of otospongiotic sensorineural losses. Am J Otol. Mar 1989;10(2):99-107. [Medline].

  6. Dornhoffer JL, Bailey HA Jr, Graham SS. Long-term hearing results following stapedotomy. Am J Otol. Sep 1994;15(5):674-8. [Medline].

  7. Hannley MT. Audiologic characteristics of the patient with otosclerosis. Otolaryngol Clin North Am. Jun 1993;26(3):373-87. [Medline].

  8. Hinojosa R, Marion M. Otosclerosis and sensorineural hearing loss: a histopathologic study. Am J Otolaryngol. Sep-Oct 1987;8(5):296-307. [Medline].

  9. Hough JV, Dyer RK Jr. Stapedectomy. Causes of failure and revision surgery in otosclerosis. Otolaryngol Clin North Am. Jun 1993;26(3):453-70. [Medline].

  10. Iurato S, Ettorre GC, Onofri M, Davidson C. Very far-advanced otosclerosis. Am J Otol. Sep 1992;13(5):482-7. [Medline].

  11. Linthicum FH Jr. Histopathology of otosclerosis. Otolaryngol Clin North Am. Jun 1993;26(3):335-52. [Medline].

  12. Rama-Lopez J, Cervera-Paz FJ, Manrique M. Cochlear implantation of patients with far-advanced otosclerosis. Otol Neurotol. Feb 2006;27(2):153-8. [Medline].

  13. Rizer FM, Lippy WH. Evolution of techniques of stapedectomy from the total stapedectomy to the small fenestra stapedectomy. Otolaryngol Clin North Am. Jun 1993;26(3):443-51. [Medline].

  14. Roland PS, Meyerhof WL. Otosclerosis. In: Head and neck Surgery-Otolaryngology. Vol 2. 1998:2083-97.

  15. Willis R. Stapedectomy--past and present. Ann Acad Med Singapore. Sep 1991;20(5):680-5. [Medline].

  16. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. Laryngoscope. Feb 2006;116(2):201-6. [Medline].

Further Reading

Keywords

otosclerosis, hearing loss, conductive hearing loss, sensorineural hearing loss, SNHL, deafness, metabolic bone disease, otic capsule, ossicles, tinnitus, disequilibrium, vertigo, otosclerotic inner ear syndrome, secondary endolymphatic hydrops, Ménière syndrome, otitis media, aural atresia, tympanosclerosis, Paget disease, osteogenesis imperfecta

Contributor Information and Disclosures

Author

Peter S Roland, MD, Professor, Department of Neurological Surgery, Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, Director of Clinical Center for Auditory, Vestibular and Facial Nerve Disorders, Chief of Pediatric Otology, University of Texas Southwestern Medical Center; Adjunct Professor of Communicative Disorders, School of Human Development.
Peter S Roland, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American Laryngological Rhinological and Otological Society, American Neurotology Society, American Otological Society, North American Skull Base Society, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Alcon labs Honoraria Speaking and teaching; GSK Honoraria Speaking and teaching; Advanced Bionics Honoraria Board membership; Cochlear corp Honoraria Board membership; Med El corp travel grants Speaking and teaching; Insight vision Consulting fee Consulting

Medical Editor

Orval Brown, MD, Director of Otolaryngology Clinic, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center at Dallas
Orval Brown, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics, American Bronchoesophagological Association, American College of Surgeons, American Medical Association, American Society of Pediatric Otolaryngology, Society for Ear, Nose and Throat Advances in Children, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

John E McClay, MD, Assistant Professor, Department of Otolaryngology, Division of Pediatric Otolaryngology, Children's Medical Center, University of Texas Southwestern Medical School
John E McClay, MD is a member of the following medical societies: American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, and American Medical Association
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting; Pfizer Honoraria Consulting

Chief Editor

Glenn C Isaacson, MD, FACS, FAAP, Professor of Otolaryngology-Head and Neck Surgery and Pediatrics, Temple University School of Medicine
Glenn C Isaacson, MD, FACS, FAAP is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics, American Bronchoesophagological Association, American College of Surgeons, American Laryngological Rhinological and Otological Society, American Society of Pediatric Otolaryngology, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Covidien Honoraria Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.